Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Krystal Biotech (KRYS) Work In Process (2023 - 2025)

Krystal Biotech (KRYS) has disclosed Work In Process for 3 consecutive years, with $15.2 million as the latest value for Q4 2025.

  • Quarterly Work In Process rose 41.71% to $15.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $15.2 million through Dec 2025, up 41.71% year-over-year, with the annual reading at $15.2 million for FY2025, 41.71% up from the prior year.
  • Work In Process hit $15.2 million in Q4 2025 for Krystal Biotech, down from $15.8 million in the prior quarter.
  • In the past five years, Work In Process ranged from a high of $15.8 million in Q3 2025 to a low of $3.2 million in Q4 2023.
  • Historically, Work In Process has averaged $9.7 million across 3 years, with a median of $8.9 million in 2025.
  • Biggest five-year swings in Work In Process: skyrocketed 235.3% in 2024 and later soared 39.42% in 2025.
  • Year by year, Work In Process stood at $3.2 million in 2023, then surged by 235.3% to $10.7 million in 2024, then soared by 41.71% to $15.2 million in 2025.
  • Business Quant data shows Work In Process for KRYS at $15.2 million in Q4 2025, $15.8 million in Q3 2025, and $15.3 million in Q2 2025.